Dicyanogold effects on lymphokine production

Area of Science:

• Immunology
• Pharmacology
• Molecular Biology

Background:

• Gold compounds are used to treat Rheumatoid Arthritis (RA).
• Dicyanogold(I) is a known metabolite of gold-based drugs.
• Transcription factors like AP-1 and CREB regulate immune responses relevant to RA.

Purpose of the Study:

• To investigate the effects of dicyanogold(I) on lymphokine production.
• To explore the potential mechanism of action of gold drugs in RA.

Main Methods:

• Using Jurkat cells (CD4+ lymphocyte model) to study AP-1 binding and IL-2 synthesis.
• Using THP-1 cells (macrophage model) to study CREB binding and IL-1beta synthesis.
• Assessing mRNA and protein levels of key cytokines.

Main Results:

• Dicyanogold(I) inhibited AP-1 DNA binding and IL-2 production in Jurkat cells.
• Dicyanogold(I) inhibited CREB DNA binding and IL-1beta production in THP-1 cells.
• These findings suggest dicyanogold(I) interferes with crucial transcription factors.

Conclusions:

• Gold drugs may exert their therapeutic effects by interacting with transcription factors.
• This interaction modulates immune activation pathways implicated in Rheumatoid Arthritis.
• Dicyanogold(I) provides a molecular target for understanding gold's anti-arthritic action.